checkAd

     109  0 Kommentare Juva Life Validates Discovery Strategy and Technology Platform, Leading to Discovery of Second Novel Drug Candidate, JUVA-041 Nominated for Pre-Clinical Development - Seite 2

    For further information, please contact:

    Juva Life Investor Relations

    Tel: +1 833-333-5882 (JUVA)

    Email: inquiries@juvalife.com

    Forward Looking Statement

    This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

    Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

    The CSE does not accept responsibility for the adequacy or accuracy of this release.


    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Juva Life Validates Discovery Strategy and Technology Platform, Leading to Discovery of Second Novel Drug Candidate, JUVA-041 Nominated for Pre-Clinical Development - Seite 2 Methodical, Efficient Approach to Drug Discovery Advances Non-Cannabinoid Molecule as Unique Development CandidateVANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) - Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva …